| Market Cap | 3.03M | P/E | - | EPS this Y | 95.70% | Ern Qtrly Grth | - |
| Income | -18.82M | Forward P/E | -5.14 | EPS next Y | 94.10% | 50D Avg Chg | 1.00% |
| Sales | 15.02M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -58.00% |
| Dividend | N/A | Price/Book | 0.25 | EPS next 5Y | - | 52W High Chg | -94.00% |
| Recommedations | 1.50 | Quick Ratio | 0.65 | Shares Outstanding | 1.35M | 52W Low Chg | 50.00% |
| Insider Own | 0.04% | ROA | -32.39% | Shares Float | 1.08M | Beta | 0.83 |
| Inst Own | 0.92% | ROE | -251.60% | Shares Shorted/Prior | 94.89K/48.50K | Price | 0.72 |
| Gross Margin | 53.86% | Profit Margin | -74.01% | Avg. Volume | 521,908 | Target Price | 58.63 |
| Oper. Margin | -59.71% | Earnings Date | Aug 8 | Volume | 111,973 | Change | -0.41% |
NovaBay Pharmaceuticals, Inc. develops and sells eyecare and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; Avenova Eye Health Support antioxidant-rich oral supplements; Avenova Lubricating Eye Drops for instant relief; NovaWipes by Avenova; Avenova WarmEye Compress to soothe the eyes; and the i-Chek by Avenova to monitor physical eyelid health. The company also provides wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands. It sells its products through the company's web stores, third-party online retailers and distribution partners. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.
| Ladenburg Thalmann | Buy | Aug 11, 23 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Kunin Audrey | Chief Product Office.. Chief Product Officer | Dec 06 | Sell | 1.81 | 1 | 2 | 12/07/22 | |
| Kunin Jeffrey | President, DERMAdoct.. President, DERMAdoctor, LLC | Dec 06 | Sell | 1.81 | 1 | 2 | 12/07/22 | |
| Kunin Audrey | Chief Product Office.. Chief Product Officer | Nov 21 | Sell | 2.10490 | 5,960 | 12,545 | 1 | 12/05/22 |
| Kunin Jeffrey | President, DERMAdoct.. President, DERMAdoctor, LLC | Nov 21 | Sell | 2.10490 | 5,960 | 12,545 | 1 | 12/05/22 |
| Hall Justin | CEO, GC and Director CEO, GC and Director | Sep 14 | Buy | 0.15 | 10,000 | 1,500 | 83,172 | 09/16/22 |
| Kunin Jeffrey | President, DERMAdoct.. President, DERMAdoctor, LLC | Sep 14 | Sell | 0.1582 | 291,368 | 46,094 | 208,632 | 09/16/22 |
| Kunin Audrey | Chief Product Office.. Chief Product Officer | Sep 14 | Sell | 0.1582 | 291,368 | 46,094 | 208,632 | 09/16/22 |